Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -13M | 71.9% |
| Cost of Revenue | 13M | 71.9% |
| Operating expense | 31M | 50.1% |
| Net Income | -28M | 554% |
| EBITDA | -31M | 50.1% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 224M | 8.1% |
| Total Liabilities | 57M | 4.6% |
| Total Equity | 167M | 11.8% |
| Shares Outstanding | 48M | 0% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -18M | 0.3% |
| Cash from investing | -17,000 | 41.4% |
EPS
Financial Highlights for Cassava Sciences in Q3 '24
Gross Profit stood at -13M, marking a 71.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 13M, a -71.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 31M, showing a -50.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -28M, showing a -554% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -31M, showing a 50.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Cassava Sciences faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.
